Phase 2 Licensing Deal Benchmarks

Phase 2 represents the most active deal-making stage in biopharma licensing, where proof-of-concept data transforms asset valuations. Median total deal values at Phase 2 reach $1.6B, with upfront payments between $144M and $401M. This stage offers the optimal balance of de-risking and upside potential for both licensors and licensees.

Phase 2 deal structures balance upfront and milestone payments effectively. The 16/84 upfront/milestone split reflects moderate clinical risk. Development milestones average $345M, while regulatory milestones of $552M and commercial milestones of $483M reward successful progression to market.

Royalty rates at Phase 2 range from 11.8% to 19.3%, the mid-range of industry norms. Assets with pivotal-ready Phase 2 data (clear efficacy signal, manageable safety, well-defined patient population) command premium terms approaching Phase 3 valuations, while assets with mixed or preliminary data trade at discounts.